Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist.
about
Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survivalModeling Pancreatic Endocrine Cell Adaptation and Diabetes in the Zebrafish.Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.The New Biology and Pharmacology of Glucagon.Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice.The glucoregulatory actions of leptin.Glucagon antagonism in islet cell proliferation.Kinetics of functional beta cell mass decay in a diphtheria toxin receptor mouse model of diabetes.Partners for life.Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetesRegulation of amino acid metabolism and alpha cell proliferation by glucagon.Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.Problem or solution: The strange story of glucagon.Pancreatic islet-autonomous insulin and smoothened-mediated signalling modulate identity changes of glucagon α-cellsSIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic miceDeletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia
P2860
Q28830385-688DCC2F-F7FA-4007-A3EB-47AB6A4CA7A8Q37607133-AE9AEAAC-2E25-4697-AD29-D1B9D0F30032Q38795246-64785095-8BFC-4465-AE6F-866D19F7F89AQ38919742-316504CB-BB8B-4E70-9F15-342758367DFBQ38988157-EEE2AE39-F68C-4367-B0E9-2504321E5005Q39003343-86395BB3-015F-4A7A-97AB-99EFAC693DD3Q41689705-931A742E-6008-461B-A97F-ABE20860E71BQ41709975-361A0588-5DFD-4129-AEDE-44C1DAB05AF7Q42172185-FE4CEB67-2B79-4FC3-83E9-AB3750DACF08Q42214143-8E2796B4-E7AB-42D6-B77E-D5C6EAFD5DC6Q42377847-59F4C30A-1F40-4752-9135-78F87E5819AEQ47190965-C2DA3E8A-20AB-4BFD-9DB1-BED213EF269AQ47625288-F592164F-8855-48A4-AB43-B119AC8B48CEQ47871565-86230F74-8560-4CD4-BEED-A0F6CB88F7F5Q48326278-269D80F8-A2DB-441E-9720-DA3B64922AC1Q50140641-899500E6-95C9-463E-8F1B-A75245A8A601Q58569394-49C20D8E-4493-421F-B625-EB06222A538EQ58726506-6E1F6B5E-F38E-45FE-AC8D-95668ACAB1EBQ58732217-D73A5938-22FE-40C7-90D8-71FA5837C5C2
P2860
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Blockade of glucagon signaling ...... y if residual β-cells persist.
@en
type
label
Blockade of glucagon signaling ...... y if residual β-cells persist.
@en
prefLabel
Blockade of glucagon signaling ...... y if residual β-cells persist.
@en
P2093
P2860
P356
P1433
P1476
Blockade of glucagon signaling ...... ly if residual β-cells persist
@en
P2093
Alvin C Powers
Fabrizio Thorel
Julie S Moyers
Maureen J Charron
Patricia M Vuguin
P2860
P356
10.7554/ELIFE.13828
P407
P577
2016-04-19T00:00:00Z